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A 42 amino acid synthetic peptide corresponding toa newly defined cysteitmkistidine-rich protein motif called B-box, from the Xenopur protein 
XNF7 has been character&d. The metal-binding stokhiometry and dissociation constant for zinc were determined by competition with the 
chromopho~c helator Br,BAPTA, demons~ating that one zinc atom binds per molecule of peptide despite the presence of seven putative metal 
ligands, and represents the t&t application of this method to measuring zinc stoichiometry of proteins and/or peptides. Cobalt binding studies 
indicate that the motif binds zinc more tightly than cobalt, that cysteines are used as ligands and that the cation is co-ordinated tetrahedrally. 
Circular dichroism and NMR studies both indicate that the B-box peptide is structured only in the presence of zinc, copper and to a lesser extent 
cobalt. 
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1. INTRODUCTION 
Many cellular processes uch as tran~~ption, RNA 
processing and replication are regulated by protein- 
DNA and protein-protein interactions. For this pur- 
pose numerous protein structural motifs such as the 
homeodomain, basic domain, leucine zipper, helix- 
loop-helix and the zinc finger have evolved (for reviews 
see [l-3]). Each of these domains is usually character- 
ised by the conservation of some primary sequence 
which generally leads to a conservation of tertiary struc- 
ture [4]. Amongst these motifs are a number of well- 
characterised zinc-binding domains which include the 
classical TFIIIA-like zinc finger and the steroid recep- 
tor and GAL4 DNA-boding domains (for reviews see 
[5&J). A common feature of these types of structural 
motifs is the use of cysteines and/or histidines for zinc 
binding and tertiary structure stabilisation, although 
there appears to be little overall structural similarity. A 
number of other putative cysteine~stidine-rich metal 
binding motifs have been identified on the basis of se- 
quence homology searches [7-91 and it is increasingly 
clear that there are a large number of diverse metal- 
binding domains which use cysteine and histidine resi- 
dues for metal ligation and structural framework for- 
mation. Interestingly not all of these domains have 
DNA-binding properties, for example the cysteine-rich 
*Corresponding author. Fax: (44) (71) 269 3093. 
domain of protein kinase C which is implicated in bind- 
ing phorbol esters [lo]. The HIV Tat protein is another 
example, where the cysteine-rich domain mediates 
homo-dimerisation in a zinc-dependent manner [ Ill. 
Recently, we have identified a novel cysteine-rich 
motif called the RING finger which defines a new fam- 
ily of proteins all of which have putative functions in- 
volving nucleic-acid interaction [12-141. The motif is 
simply defined as Cys-X(2}-Cys-X(9-27)-Cys-X( 1-3)- 
His-X(2)-Cys-X(Z)-Cys-X(4-48)~Cys-X(2)-Cys where X 
can be any amino acid and the bracketed numbers refer 
to the number of residues in the intervening sequences. 
We have shown that a peptide corresponding to the 
RING1 finger domain binds zinc with high affinity and 
DNA non-s~fic~y in a z~c-de~ndent manner [ 131. 
Amongst the RING finger family, there are a number 
of proteins which possess a second cysteine/histidine 
rich motif C-terminal to the RING finger, termed the 
B-box domain [15]. The motif is defined as Cys-X(2)- 
H&X(7)-cys-X(7) - cys-X(2)-Qs ” X(5) - His -X(2) - His 
where X can be any amino acid and the bracketed num- 
bers refer to the number of residues in the intervening 
sequences, although there are clear preferences for par- 
ticular amino acids at certain positions between differ- 
ent family members [16]. Interestingly, B-box-contain- 
ing proteins also include a predicted c+ helical coiled- 
coil domain C-terminal to the B-box, thus forming a 
tripartite motif of the RING finger, B-box and a-helical 
coiled-coil [16,17] The spacing between the three ele- 
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ments of the motif is highly conserved amongst the 
family suggesting that the positions of each domain 
relative to the others is of functional importance [16,171. 
The B-box family comprises a number of transcrip- 
tion factors, ribonucleoproteins (RNPs) and proto-on- 
cogenes which includes the ret finger protein (RFP) [18], 
PML [17-211 and T18 [17,22]. These proteins are onco- 
genie in humans and mice when found as translocations 
that include the RING and B-box fingers and a-helical 
coiled-coil domain recombined with other genes. PML 
and T18 possess two B-box like domains which appear 
to form a subgrouping of the B-box family as high- 
lighted by the presence of an extra potential cysteine 
metal ligand [16]. The other members of the family in- 
clude RPT-I [23], SS-A/R0 [24], XNF7 [25] and PwA33 
[26]. In order to understand the function of the B-box 
domain, both within this diverse family of proteins, and 
in relation to the RING finger and a-helical coiled-coil 
domains of the conserved tripartite motif, we have syn- 
thesised and purified a peptide corresponding to the 
B-box motif from the Xenopus protein XNF7. Here, we 
report the first data for the metal binding properties and 
secondary structure of a B-box domain. Due to the 
sequence similarities between B-box domains, we be- 
lieve that the data for the XNF7 B-box will be applica- 
ble to other B-box domains. 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis and purification 
The 42 amino acid peptide corresponding to the B-Box motif (resi- 
dues 219-260 in the XNF7 sequence; [25]) was synthesised on a Model 
431A Applied Biosystems Solid Phase Synthesiser on Chydroxymeth- 
ylphenoxycarbonyl resin using 9-fluorenylmethyloxy-carbonyl for 
temporary &-amino group protection [27]. Each amino acid was cou- 
pled twice as a hydroxybenzatriazole active ester automatically 
formed prior to use. Cleavage from the resin and deprotection of the 
peptide was achieved with 90% (v/v) trifluoroacetic acid containing 
7.5% (w/v) phenol, 0.2% (v/v) ethanedithiol, 0.5% (v/v) thioanisole and 
water at 20°C for 2 h. The yield of the 42-mer was approximately 20% 
and the peptide was subsequently purified by reverse-phase prepara- 
tive HPLC on a Brownlee Aquapore ODS Cl8 column using 0.8% 
(v/v) trifluoracetic acid and acetonitrile gradient. The purity and mo- 
lecular weight of the synthetic peptide was assessed by mass spectrom- 
etry. A few micrograms of the pure B-box peptide (peak fraction from 
HPLC separation) were analysed by Matrix-Assisted Laser Desorp- 
tion mass spectrometry [28]. A single species was observed with an 
experimental molecular weight (M[H+]) of 4,869 Da which is in excel- 
lent agreement with the calculated mass of 4,868.5 Da for the fully 
reduced form of the peptide. The concentration of B-box peptide was 
measured optically using a calculated extinction coefficient of 0.26 for 
1 mg/ml solution measured at 280 nm. The sample was purified in the 
presence of ethanedithiol and in general subsequent experiments had 
trace amounts of ethanedithiol present. 
2.2. Optical binding studies using Br,BAPTA 
Dissociation constants for the interaction of B-Box with Zn*+ were 
estimated by competition with the chromophoric chelator using the 
method originally developed for studying Ca*‘-protein interactions 
[29,30]. S-5’-Br,BAPTA (Br,BAPTA, >5’-dibromo-l,2-bis(o-amino- 
phenoxy)-ethane-N,N,K,W-tetraacetic a id) (40 PM) was titrated 
with Zn’+ in the presence and absence of 40 PM B-Box in a 10 mM 
256 
Tris-HCl buffer @H 7.5). Changes in the absorbance of the chromo- 
phore at 263 nm were monitored as Zt?’ was added. 
2.3. Optical binding studies of cobalt and zinc to the XNF7 B-box 
peptide 
Typically, a solution 
mM Tris-HCl. DH 7.5) 
(1 ml) containing 160pM of B-box peptide (10 
was titrated with solutions ofCoC1, in the same 
buffer. The peptide was also titrated against solutions of &Cl, in the 
presence of 100 PM CoCl,, The binding reaction was monitored on 
an HP 8452 diode array spectrophotometer using a 1 cm path length 
at room temperature, and each spectrum was the average of three 
recorded spectra. The spectra have been corrected by subtracting the 
contribution from the peptide and buffer alone and also for dilution 
effects. 
2.4. Circular dichroism of the XNF7 B-box peptiak 
Samples for CD spectroscopy were prepared by dilution of stock 
peptide solution into a buffer containing 20 mM PIPES (pH 7.6) plus 
either 0.05 mM EDTA or the required metal ion (as the chloride), 
generally at a concentration of 0.2 mM. Far UV CD spectra were 
recorded from 260 to 195 nm using a Jasco J-600 spectropolarimeter 
operated with a time constant of 0.5 s. The spectra were recorded at 
22°C for peptide solutions of -0.05 or 0.02 mg/ml in 2 or 5 mm fused 
silica cuvettes, respectively, and were the average of not less than four 
scans. All data reported here are presented as molar circular di- 
chroism, de, (M-’ .cm-‘) based upon a mean residue weight of 112.7. 
Residue molar ellipticity [Q] (deg.crn’. decimal-‘) may be obtained 
from the relationship [Q],, = 3,300.de. 
2.5. NMR studies of the B-box peptide 
Approximately 10 mg of peptide were dissolved in 2 ml of 10 mM 
sodium phosphate, 100 mM KC1 pH -7.5 in either 2H,0 or ‘H20 
depending on the requirements of the experiment. Small volumes of 
a concentrated ZnCl, solution were then added and the resulting 
degree of metal ligation was monitored via lD ‘H NMR techniques 
(see section 3). Once the pcptide was fully ligated (as determined from 
the NMR spectrum) the samples were concentrated to a fmal volume 
of 0.5 ml using Centricon 300 concentrators. The proton chemical 
shifts were referenced to 0.1 mM internal sodium 2,2-dimethyl-2- 
silapentane-5-sulfonate (DSS). All NMR experiments were carried out 
at 3O’C. Sample concentration varied from 1.0 to 1.5 mM as deter- 
mined by UV absorbance. Samples were not soluble at higher concen- 
trations. 1D NMR experiments were collected at 14.1 T on a Varian 
Unity spectromenter and apodised with 2 Hz line broadening and 
Fourier transformed. 
3. RESULTS AND DISCUSSION 
3.1. The B-box domain 
The boundaries of the B-box domain were chosen on 
the basis of a multiple sequence alignment of the B-box 
family and secondary structure predictions of the resul- 
tant alignment [31]. Consideration was also given to the 
known positions of the adjacent predicted a-helical 
coiled-coil domains and phosphorylation sites for 
XNF7 which exist between the RING finger domain 
and B-box [25,32]. This resulted in a domain comprising 
42 amino acids bounded by predicted /?-turn regions 
adjacent o both the C-terminal a-helical coiled-coil do- 
main and N-terminal phosphorylation sites, respec- 
tively. 
3.2. BAPTA metal binding titrations 
Initial studies using CD methods (see below) indi- 
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cated that the B-box peptide preferentially bound zinc. 
In order therefore to determine both the number of zinc 
atoms bound per molecule of peptide and also the disso- 
ciation constant for zinc, we used a method developed 
for monitoring calcium binding to calmodulin [29,30]. 
This method works equally well for zinc and has the 
advantage that it can be carried out at low peptide 
concentrations. Thus, the chromophore Br,BAFTA 
was titrated with zinc in the presence and absence of 
B-Box peptide as described in section 2 and the results 
are shown in Fig. 1. Titrations performed in the absence 
of peptide were used to estimate a dissociation constant 
for the Zn”-dye complex. The data were analysed using 
standard Marquardt non-linear least-squares methods 
with the assumption of 1: 1 stoichiometry. The dissocia- 
tion constant was calculated to be 92 + 20 nM (average 
of three determinations). 
Data obtained in the presence of peptide were analy- 
sed using the method developed by Linse et al. [29,30]. 
The data could be adequately described with the as- 
sumption that B-Box binds a single Zn’+ ion with a 
dissociation constant of 61 ? 12 nM (average of four 
determinations). However, we cannot exclude the possi- 
bility that B-Box binds a second Zn2+ ion with signifi- 
cantly lower affinity. Computer simulations (not 
shown) demonstrate that the binding of a second Zn2’ 
ion with a dissociation constant > 10 ,uM or higher 
would be observed with this method suggesting that any 
additional Zn2+ binding would be non-specific. A com- 
parison of the B-box sequences suggests that up to seven 
residues could ligate the divalent cation. However, the 
‘+ 
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Fig. 1. Br,BAPTA-zinc competition assays. Absorbance at 263 nm 
(A& is plotted against zinc concentration for the titration of 40 PM 
5,5’-Br,BAPTA in the presence (filled boxes) and absence (open 
boxes) of 40 PM B-Box. The initial and final AX3 values are higher 
in the presence of B-Box which is due to peptide absorption and is 
assumed not to change upon Zn2+ binding. 
data presented above precludes this possibility. The re- 
maining conserved residues may be important for pro- 
tein-protein interactions or in stabilisation of the terti- 
ary fold. Another possible role for the other conserved 
ligands could be the formation of intermolecular dimers 
using divalent cations as observed for the HIV Tat pro- 
tein [ 111, which could explain the precipitation observed 
in the presence of excess divalent cation (see below). 
3.3. Optical metal-binding studies 
The optical spectral properties of cobalt bound to 
synthetic zinc finger peptides and purified proteins have 
been studied extensively and provide information both 
on the nature of the amino acid ligands and the geome- 
try of ligation [33-371. A series of titrations of the puri- 
fied XNF7 B-box peptide with solutions of cobalt 
showed absorption maxima at a = 640-660 nm and 
shoulders at il = 320 and 365 nm (Fig. 2). The 640-660 
nm maxima are due to d-d transitions of Co (II) in a 
tetrahedral co-ordination, whilst the charge transfer 
bands at 300-365 mn are due to S-Co (II) co-ordination 
[33]. The results shown in Fig. 2 are therefore consistent 
with cobalt binding to the peptide using a number of 
cysteines as ligands in a tetrahedral co-ordination sys- 
tem. During the course of the cobalt titration, we ob- 
served no changes in the overall spectrum except at high 
concentrations of cobalt when the peptide precipitated 
and diminished the absorption characteristics of the co- 
balt-B-box complex. It should be noted, that CD meas- 
urements for the B-box peptide and cobalt (see below) 
show that cobalt, compared to zinc or copper, does not 
induce maximal secondary structure formation. There- 
fore, interpretations of the optically observed cobalt- 
peptide complex may be misleading. However, it is clear 
that titrations of the B-box peptide (160 PM) with zinc 
(10 ,uM) in the presence of 100 PM cobalt diminishes the 
characteristic cobalt transitions (Fig. 2b), suggesting 
that zinc displaces the cobalt and binds more tightly to 
the peptide than cobalt. However, it is possible that the 
metal binding sites for zinc and cobalt could be overlap- 
ping and not identical. 
3.4. Circular dichroism and ID NMR studies 
Structure formation upon metal ligation was moni- 
tored using circular dichroism and NMR techniques. 
Fig. 3 shows the far-UV CD spectrum of the B-box 
peptide in aqueous solution and in the same buffer con- 
taining zinc. This region of the CD spectrum monitors 
the secondary structure content of the peptide. The 
spectrum of B-box in aqueous solutions shows an in- 
tense band at -198 nm indicating that the peptide con- 
tains a high percentage of random or non-regular sec- 
ondary structures. The addition of Zn2+ produces a sig- 
nificant increase in the amount of regular secondary 
structure, as shown by reduction in the intensity of the 
198 nm band and the appearance of significant intensity 
at wavelengths >210 mn. The intensity observed at 222 
257 
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Fig. 2. Co’+ titration of the B-box peptide. (A) The spectra shown represent a single titration experiment of B-box peptide (158 yM). Co’* was 
added from 2 to 27 PM in 5 FM increments and from 27 to 57 PM in 10 PM increments. (B) The spectra shown represents the addition of 10 FM 
Zn2+ (lower line) to a cobalt-peptide complex comprising 158 ,uM peptide and 100 ,uM Co*’ (upper line). 
nm in the presence of Zn*+ suggests that the metal in- 
duces a maximum of B-25% cl-helix. The addition of 
excess EDTA to the Zn*’ containing solution reversed 
the Zn*” induced change, as expected (see Fig. 3). Other 
divalent cations have been tested to determine whether 
they induce changes in secondary structure, the results 
of which are shown in Fig. 3. Cd*+ and Ca2* induced 
only small changes in comparison to that observed with 
Zn*+. Cu*’ binding induces a similar amount of helix as 
Zn*+ as does Co’+ but to a lesser extent (Fig. 3). Re- 
cently, copper has been shown to bind with high affinity 
to the normally zinc-binding estrogen receptor DNA- 
binding domain, using two cysteines per copper atom 
for ligation. The physiological significance of this obser- 
vation is however unclear and may be artefactual [34]. 
In order to monitor any conformational changes that 
occur upon ligation of metal ion, 1D NMR spectra were 
collected in the presence and absence of zinc. Fig. 4A 
258 
shows a spectrum of the peptide before addition of zinc. 
As seen with the CD data, there is no evidence for 
si~ifi~ant structure in the apo-form of the peptide. 
However, once the peptide is fully ligated a number of 
spectral features appear (Fig. 4B) which are indicative 
of both secondary and tertiary structure formation. 
Two of the aliphatic resonances are shifted upfield by 
at least 0.5 ppm to - 0.4 ppm. Such large upfield shifts 
are characte~stic of the aliphatic groups coming into 
close proximity to aromatic ring currents as a result of 
tertiary structure formation. Also, a number of ColH 
resonances are shifted downfield of the HDO signal 
which is consistent with the formation of an anti-paral- 
lel /I-sheet 1391. The chemical shifts of the aromatic ring 
protons move si~fi~ntly downfield upon zinc liga- 
tion, especially the C2 protons of the histidine rings. 
This shift is consistent with the expected change in 
chemical environment which is either a result of direct 
Volume 335, number 2 FEBS LETTERS December 1993 
metal ligation or indirectly by subsequent tertiary struc- 
ture formation. Finally, amide protons are only pro- 
tected against exchange with bulk solvent in the pres- 
ence of zinc suggesting that only when ligated does the 
peptide form a stable hydrogen-bonding network. This 
is indicative of secondary structure formation. 
3.5. Summary 
A synthetic peptide co~esponding to the newly de- 
fined XNF7 B-box motif has no secondary structure in 
the absence of divalent metal ions, as shown by CD and 
1D NMR. The peptide however undergoes a structural 
transition upon the addition of zinc or copper. Metal- 
binding studies of the B-box domain using the chromo- 
phore BrzBAPTA indicate that the molar binding stoi- 
chiometry for Zn2’ to peptide is 1: I with a measured Kd 
of 61 + 12 nM. Cobalt-binding studies show that cobalt 
binds to the B-box peptide tetrahedrally using cysteine 
as ligands but less tightly than zinc and that zinc can 
displace the cobalt. Together, these metal-binding stud- 
ies suggest hat not all of the conserved cysteines and/or 
histidines are involved in direct metal ligation. This 
poses the question as to what is the function of the 
non-liganded cysteines and/or histidines in the B-box 
domain. One possible function could be inter-molecular 
dimerisation, as observed for the HIV Tat protein [l I], 
although the prel~ina~ NMR m~surements reported 
here suggest a B-box monomer in solution. This ques- 
tion must await further investigation. 
I / I 
200 210 220 230 240 250 2 
Wavelength (nm) 
Fig. 3. CD spectra of XNF7 B-box peptide. Peptide concentration was 
approximately 4 PM in 5 mm cuvettes. The concentration of the 
divalent cation was 0.2 mM and was added as the chloride. EDTA was 
added in excess to the Znz~-containing solution after complexation 
with the peptide. 
A 
8 7 6 5 PPm 
k 
trIlIIII,111I(Ii1(,1,III,IIII,IIII/iIIIIrII~ 
8 7 6 5 4 3 2 ppm 
Fig. 4. One dimensional ‘H NMR spectra in 2Hz0. Panel A shows the 
peptide (- 1 mM) before addition of Zn’+ and panel B after addition 
of 1 mM Zn2’. Both spectra were collected at pH 7.5 and 303 K. The 
large peak in the aliphatic region of panel B is ethanedithiol. 
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